NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

Search

Genmab A-S

Atidarymo kaina

1,283.5 -2.1

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1268.5

Max

1324.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

2.1B

3.8B

Pardavimai

901M

6.4B

P/E

Sektoriaus vid.

10.917

73.239

Pelnas, tenkantis vienai akcijai

60.121

Pelno marža

59.696

Darbuotojai

2,682

EBITDA

-297M

1.8B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-1.49% downside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.8B

87B

Ankstesnė atidarymo kaina

1285.6

Ankstesnė uždarymo kaina

1283.5

Genmab A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-10 15:16; UTC

Pagrindinės rinkos jėgos

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

2024-04-03 13:04; UTC

Įsigijimai, susijungimai, perėmimai

Correction to Genmab Article

2024-04-03 08:08; UTC

Įsigijimai, susijungimai, perėmimai

Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio

2024-12-10 07:05; UTC

Rinkos pokalbiai

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Akcijų palyginimas

Kainos pokytis

Genmab A-S Prognozė

Kainos tikslas

By TipRanks

-1.49% į apačią

12 mėnesių prognozė

Vidutinis 2,493.35 DKK  -1.49%

Aukščiausias 3,320 DKK

Žemiausias 308.417 DKK

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Genmab A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

3

Pirkti

2

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.